Skip to main content

Ovarian Cancer

Featured Article
According to a new study in JAMA, medically underserved Medicare beneficiaries with breast or ovarian cancer rarely receive BRCA tests, which often help with health-related decision-making.
A class of antitumor compounds known as HDAC inhibitors offer potential for the treatment of ovarian cancer with mutations in the ARID1A gene, a new study suggests. 
Back to Top